Current Trends in Cardiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Current Trends in Cardiology (2023) Volume 7, Issue 11

Understanding Myocardial Fibrosis: Causes, Symptoms, and Treatment

Reto Auer *

Department of Medicine, University of Lausanne, Switzerland.

*Corresponding Author:
Reto Auer
Department of Medicine,
University of Lausanne

Received:30-Oct-2023,Manuscript No. AACC-23-127597; Editor assigned:02-Nov-2023,PreQC No. AACC-23-127597(PQ); Reviewed:16-Nov-2023,QC No. AACC-23-127597; Revised:20-Nov-2023, Manuscript No. AACC-23-127597 (R); Published:28-Nov-2023,DOI:10.35841/aacc-7.11.219

Citation: Hays A. Understanding myocardial fibrosis: Causes, symptoms, and treatment. Curr Trend Cardiol.2023;7(11):219

Visit for more related articles at Current Trends in Cardiology


Myocardial fibrosis is a condition characterized by excessive deposition of collagen fibers in the myocardium, the muscular tissue of the heart. This condition can lead to stiffening of the heart muscle, impaired cardiac function, and ultimately heart failure. While it often accompanies other cardiac diseases, it can also occur independently. Understanding the causes, symptoms, and treatment options for myocardial fibrosis is crucial for effective management and prevention of its complications.[1,2].

Myocardial fibrosis can result from various factors, including chronic conditions such as hypertension, diabetes, and coronary artery disease. These conditions can lead to sustained injury and inflammation of the heart tissue, prompting the deposition of collagen as part of the healing process. Additionally, exposure to toxins, certain medications, and genetic predisposition can contribute to the development of myocardial fibrosis. Chronic alcohol consumption and autoimmune disorders are also known to increase the risk of this condition.The symptoms of myocardial fibrosis can vary depending on the extent and severity of fibrotic changes in the heart. In the early stages, patients may experience fatigue, shortness of breath, and exercise intolerance. As the condition progresses, individuals may develop palpitations, chest pain, and fluid retention, leading to swelling in the legs and abdomen. In severe cases, myocardial fibrosis can result in arrhythmias, heart failure, and sudden cardiac death. Timely recognition and evaluation of these symptoms are essential for early diagnosis and intervention [3,4].

Diagnosing myocardial fibrosis often involves a combination of clinical assessment, imaging studies, and laboratory tests. Electro CardioGraphy (ECG) may reveal abnormal heart rhythms or conduction disturbances indicative of myocardial dysfunction. Echocardiography, cardiac MRI, and CT scans can provide detailed images of the heart, allowing clinicians to visualize structural abnormalities and assess myocardial function. Biomarkers such as troponin and Brain Natriuretic Peptide (BNP) may be elevated in the blood, indicating cardiac injury and dysfunction.[5,6].


The management of myocardial fibrosis aims to alleviate symptoms, improve cardiac function, and prevent disease progression. Lifestyle modifications, including regular exercise, a balanced diet, and smoking cessation, are essential for overall cardiovascular health. Pharmacological interventions such as Angiotensin-Converting Enzyme (ACE) inhibitors, beta-blockers, and diuretics may be prescribed to control blood pressure, reduce cardiac workload, and manage fluid retention. In some cases, ant fibrotic medications targeting specific pathways involved in collagen deposition may be considered.[7,8].



Surgical interventions, including Coronary Artery Bypass Grafting (CABG) and Cardiac Resynchronization Therapy (CRT), may be necessary for patients with advanced myocardial fibrosis and coronary artery disease. In select cases, heart transplantation may be the only viable option for patients with end-stage heart failure refractory to medical therapy. Regular monitoring and follow-up care are essential to assess treatment response, detect complications, and adjust management strategies accordingly. Advances in research have provided insights into the molecular mechanisms underlying myocardial fibrosis, paving the way for the development of novel therapeutic approaches. Targeted therapies aimed at modulating fibroblast activity, inhibiting profibrotic signalling pathways, and promoting myocardial regeneration hold promise for improving outcomes in patients with myocardial fibrosis. Furthermore, personalized medicine approaches utilizing genetic testing and biomarker profiling may enable more precise risk stratification and treatment selection in the future.[



  1. Annane D. Septic shock. Lancet. 2005;365(9453):63-78.
  2. Google Scholar

  3. Astiz ME. Septic shock. Lancet. 1998;351(9114):1501-5.
  4. Google Scholar

  5. Parrillo JE. Pathogenetic mechanisms of septic shock. J Med. 1993;328(20):1471-7.
  6. Indexed at, Google Scholar, Cross Ref

  7. Cecconi M. Sepsis and septic shock. Lancet. 2018;392(10141):75-87.
  8. Google Scholar

  9. Howell MD. Management of sepsis and septic shock. Jama. 2017;317(8):847-8.
  10. Indexed at, Google Scholar, Cross Ref

  11. King EG. Pathophysiologic mechanisms in septic shock. Lab Invest. 2014;94(1):4-12.
  12. Indexed at, Google Scholar, Cross Ref

  13. Seymour CW. Septic shock: advances in diagnosis and treatment. Jama. 2015;314(7):708-17.
  14. Indexed at, Google Scholar, Cross Ref

  15. Nduka OO, Parrillo JE. The pathophysiology of septic shock. Crit Care Nurs Clin. 2011;23(1):41-66.
  16. Google Scholar

  17. Angus DC. Severe sepsis and septic shock. J Med. 2013;369(9):840-51.
  18. Indexed at, Google Scholar, Cross Ref

  19. Rackow EC. Pathophysiology and treatment of septic shock. Jama. 1991;266(4):548-54.
  20. Indexed at, Google Scholar, Cross Ref

Get the App